EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defactinib in Combination with Mitotane Can Be an Effective Treatment in Human Adrenocortical Carcinoma

Henriett Butz iD, Lőrinc Pongor, Lilla Krokker, Borbála Szabó, Katalin Dezső, Titanilla Dankó, Anna Sebestyén, Dániel Sztankovics iD, József Tóvári iD, Sára Eszter Surguta, István Likó, Katalin Mészáros und 7 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Henriett Butz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and the National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre, 7-9 Rath Gy…. Hauptthemen laut MEDLINE: Mitotane, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian Scientific Research Grant of the National Research, Development and Innovation (NRDI) Office Fund of the Ministry of Culture and Innovation under the…, Hungarian Thematic Excellence Program, National Research, Development and Innovation (NRDI) Office Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adrenocortical carcinoma (ACC) is an aggressive cancer with a poor prognosis. Mitotane, the only FDA-approved treatment for ACC, targets adrenocortical cells and reduces cortisol levels. Although it remains the cornerstone of systemic therapy, its overall impact on long-term outcomes is still a matter of ongoing clinical debate. Drug repurposing is a cost-effective way to identify new therapies, and defactinib, currently in clinical trials as part of combination therapies for various solid tumours, may enhance ACC treatment. We aimed to assess its efficacy in combination with mitotane. We tested the combination of mitotane and defactinib in H295R, SW13, and mitotane-sensitive and -resistant HAC15 cells, using functional assays, transcriptomic profiling, 2D and 3D cultures, bioprinted tissues, and xenografts. We assessed drug interactions with NMR and toxicity in vivo, as mitotane and defactinib have never been previously administered together. Genomic data from 228 human ACC and 158 normal adrenal samples were also analysed. Transcriptomic analysis revealed dysregulation of focal adhesion along with mitotane-related pathways. Focal adhesion kinase (FAK) signalling was enhanced in ACC compared to normal adrenal glands, with PTK2 (encoding FAK) upregulated in 44% of tumour samples due to copy number alterations. High FAK signature scores correlated with worse survival outcomes. FAK inhibition by defactinib, both alone and in combination with mitotane, showed effective anti-tumour activity in vitro. No toxicity or drug—drug interactions were observed in vivo. Combination treatment significantly reduced tumour volume and the number of macrometastases compared to those in the mitotane and control groups, with defactinib-treated tumours showing increased necrosis in xenografts. Defactinib combined with conventionally used mitotane shows promise as a novel combination therapy for ACC and warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitotaneAdrenocortical CarcinomaAdrenal Cortex NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysFemaleGene Expression Regulation, NeoplasticFocal Adhesion Kinase 1

Stichwörter der Autor:innen

3D modeladrenocortical cancerdefactinibdrug repurposingfocal adhesion signallingtargeted therapy

Substanzen

MitotaneFocal Adhesion Kinase 1

Autor:innen und Institutionen

  • Department of Molecular Genetics and the National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre, 7-9 Rath Gyorgy utca, H-1122 Budapest, Hungary.
  • Department of Oncology Biobank, National Institute of Oncology, Comprehensive Cancer Centre, 7-9 Rath Gyorgy utca, H-1122 Budapest, Hungary.
  • HUN-REN-OOI-TTK-HCEMM Oncogenomics Research Group, 7-9 Rath Gyorgy utca, H-1122 Budapest, Hungary.
  • Department of Laboratory Medicine, Semmelweis University, 4 Nagyvarad ter, H-1089 Budapest, Hungary.
  • Cancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine, 9 Budapesti ut, H-6728 Szeged, Hungary.
  • Department of Pathology and Experimental Cancer Research, Semmelweis University, 26. Ulloi ut, H-1085 Budapest, Hungary.

ORCID-Profile: Henriett Butz, Dániel Sztankovics, József Tóvári, Andrea Deák, Ramóna Vida, Erika Tóth, Péter Igaz, Attila Patócs

Förderung

  • Hungarian Scientific Research Grant of the National Research, Development and Innovation (NRDI) Office Fund of the Ministry of Culture and Innovation under the…
  • Hungarian Thematic Excellence Program
  • National Research, Development and Innovation (NRDI) Office Fund
  • New National Excellence Program of the Ministry of Human Capacities
  • Bolyai Research Fellowship of the Hungarian Academy of Sciences

Zitieren

APA

Butz, H., Pongor, L., Krokker, L., Szabó, B., Dezső, K., Dankó, T., Sebestyén, A., Sztankovics, D., Tóvári, J., Surguta, S. E., Likó, I., Mészáros, K., Deák, A., Fekete, F., Vida, R., Báthory-Fülöp, L., Tóth, E., Igaz, P., & Patócs, A. (2025). Defactinib in Combination with Mitotane Can Be an Effective Treatment in Human Adrenocortical Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136539

Vancouver

Butz H, Pongor L, Krokker L, Szabó B, Dezső K, Dankó T, et al. Defactinib in Combination with Mitotane Can Be an Effective Treatment in Human Adrenocortical Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136539

BibTeX
@article{Butz2025,
  author = {Butz, Henriett and Pongor, Lőrinc and Krokker, Lilla and Szabó, Borbála and Dezső, Katalin and Dankó, Titanilla and Sebestyén, Anna and Sztankovics, Dániel and Tóvári, József and Surguta, Sára Eszter and Likó, István and Mészáros, Katalin and Deák, Andrea and Fekete, Fanni and Vida, Ramóna and Báthory-Fülöp, László and Tóth, Erika and Igaz, Péter and Patócs, Attila},
  title = {Defactinib in Combination with Mitotane Can Be an Effective Treatment in Human Adrenocortical Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136539}
}
Kostenlos starten →